Evoke Pharma ROA 2013-2025 | EVOK
Current and historical return on assets (ROA) values for Evoke Pharma (EVOK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Evoke Pharma ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-09-30 | $-0.01B | $0.02B | -30.30% |
| 2025-06-30 | $-0.01B | $0.02B | -31.25% |
| 2025-03-31 | $0.00B | $0.02B | -26.67% |
| 2024-12-31 | $-0.01B | $0.01B | -35.71% |
| 2024-09-30 | $-0.01B | $0.01B | -53.33% |
| 2024-06-30 | $-0.01B | $0.01B | -71.79% |
| 2024-03-31 | $-0.01B | $0.01B | -88.89% |
| 2023-12-31 | $-0.01B | $0.01B | -94.12% |
| 2023-09-30 | $-0.01B | $0.01B | -82.05% |
| 2023-06-30 | $-0.01B | $0.01B | -72.73% |
| 2023-03-31 | $-0.01B | $0.01B | -65.31% |
| 2022-12-31 | $-0.01B | $0.01B | -66.67% |
| 2022-09-30 | $-0.01B | $0.01B | -68.09% |
| 2022-06-30 | $-0.01B | $0.01B | -69.57% |
| 2022-03-31 | $-0.01B | $0.01B | -64.00% |
| 2021-12-31 | $-0.01B | $0.02B | -60.00% |
| 2021-09-30 | $-0.01B | $0.02B | -62.07% |
| 2021-06-30 | $-0.01B | $0.01B | -67.92% |
| 2021-03-31 | $-0.01B | $0.01B | -130.23% |
| 2020-12-31 | $-0.01B | $0.01B | -179.31% |
| 2020-09-30 | $-0.01B | $0.01B | -184.62% |
| 2020-06-30 | $-0.01B | $0.01B | -184.62% |
| 2020-03-31 | $-0.01B | $0.01B | -107.69% |
| 2019-12-31 | $-0.01B | $0.01B | -112.00% |
| 2019-09-30 | $-0.01B | $0.01B | -128.00% |
| 2019-06-30 | $-0.01B | $0.01B | -128.00% |
| 2019-03-31 | $-0.01B | $0.01B | -133.33% |
| 2018-12-31 | $-0.01B | $0.01B | -123.08% |
| 2018-09-30 | $-0.01B | $0.01B | -85.71% |
| 2018-06-30 | $-0.01B | $0.01B | -112.50% |
| 2018-03-31 | $-0.01B | $0.01B | -94.74% |
| 2017-12-31 | $-0.01B | $0.01B | -102.13% |
| 2017-09-30 | $-0.01B | $0.01B | -116.67% |
| 2017-06-30 | $-0.01B | $0.01B | -100.00% |
| 2017-03-31 | $-0.01B | $0.01B | -130.00% |
| 2016-12-31 | $-0.01B | $0.01B | -137.50% |
| 2016-09-30 | $-0.01B | $0.01B | -145.45% |
| 2016-06-30 | $-0.01B | $0.01B | -141.18% |
| 2016-03-31 | $-0.01B | $0.01B | -120.00% |
| 2015-12-31 | $-0.01B | $0.01B | -113.04% |
| 2015-09-30 | $-0.01B | $0.01B | -101.96% |
| 2015-06-30 | $-0.01B | $0.01B | -107.69% |
| 2015-03-31 | $-0.02B | $0.02B | -103.45% |
| 2014-12-31 | $-0.01B | $0.02B | -82.35% |
| 2014-09-30 | $-0.01B | $0.02B | -66.67% |
| 2014-06-30 | $-0.01B | $0.02B | -40.45% |
| 2014-03-31 | $-0.01B | $0.02B | -27.03% |
| 2013-12-31 | $0.00B | $0.01B | -15.69% |
| 2013-09-30 | $0.00B | $0.01B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |